Linker Information
General Information of This Linker
| Linker ID |
LIN0FNBQA
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
OXD-VA-PAB (PEG)
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C80H135N9O33S
|
|||||
| Isosmiles |
COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN1C=C(N=N1)CC(O)C2=CC=C(NC([C@@H](NC([C@@H](NC(COCC(NC3=CC=CC(C4=NN=C(O4)S(C)(=O)=O)=C3)=O)=O)C(C)C)=O)C)=O)C=C2
|
|||||
| InChI |
InChI=1S/C80H135N9O33S/c1-66(2)76(84-75(92)65-121-64-74(91)82-71-8-6-7-69(61-71)79-86-87-80(122-79)123(5,95)96)78(94)81-67(3)77(93)83-70-11-9-68(10-12-70)73(90)62-72-63-89(88-85-72)13-14-98-17-18-100-21-22-102-25-26-104-29-30-106-33-34-108-37-38-110-41-42-112-45-46-114-49-50-116-53-54-118-57-58-120-60-59-119-56-55-117-52-51-115-48-47-113-44-43-111-40-39-109-36-35-107-32-31-105-28-27-103-24-23-101-20-19-99-16-15-97-4/h6-12,61,63,66-67,73,76,90H,13-60,62,64-65H2,1-5H3,(H,81,94)(H,82,91)(H,83,93)(H,84,92)/t67-,73?,76-/m0/s1
|
|||||
| InChIKey |
CFEPJZGWTRWSED-GUEXIYGHSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1783.057
|
Polar area
|
471.15
|
||
|
Complexity
|
.
|
xlogp Value
|
1.2752
|
|||
|
Heavy Count
|
123
|
Rot Bonds
|
88
|
|||
|
Hbond acc
|
38
|
Hbond Donor
|
5
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
wO2024222841A1 ADC39 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 15 pM | High HER2 expression (HER2+++) | ||
| Method Description |
Cytotoxicity of ADC to SK-BR-3 cells
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
wO2024222841A1 ADC39-4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
15-25 pM
|
High HER2 expression (HER2+++) | ||
| Method Description |
Cytotoxicity of ADC to SK-BR-3 cells
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||